Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The SCOPE Trial for Postoperative Delirium
NCT06721819Phase 3Recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jun 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetaminophen in postoperative delirium (POD) (2 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Incidence of Postoperative Delirium at 7 days. Started Jun 2025; status: recruiting.
02
Drugs
acetaminophen
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on NCT06721819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721819.